Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Drug Profile

Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Alternative Names: CMV fusion peptide vaccines - Helocyte; CMVPepVax; CMVpp65-A*0201 peptide vaccine - Helocyte; Tet-CMV

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA); University of Minnesota
  • Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins; T lymphocyte cell therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections

Most Recent Events

  • 23 Aug 2017 Phase-II development is ongoing in USA (NCT02396134)
  • 04 May 2015 City of Hope and National Cancer Institute plans a phase II trial in Cytomegalovirus infections (Prevention, in HLA A*0201 cytomegalovirus-seropositive with haematological malignancies undergoing donor stem cell transplant) in USA (SC) (NCT02396134; 9178335)
  • 01 May 2015 Phase-II clinical trials in Cytomegalovirus infections (Prevention) in USA (SC) (NCT02396134)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top